PURPOSE: To prepare and evaluate a new radiotracer for molecular imaging of cell surface receptors for epidermal growth factor (EGF). METHODS: Cys-tagged EGF (cEGF) was labeled with (18)F by coupling the free thiol group of the Cys tag with N-[2-(4-[(18)F]fluorobenzamido)ethyl]maleimide ([(18)F]FBEM) to form [(18)F]FBEM-cEGF. Cell uptake, internalization and efflux of [(18)F]FBEM-cEGF were tested in human head and neck squamous carcinoma UM-SCC1 cells. In vivo tumor targeting and pharmacokinetics of the radiotracers were evaluated in UM-SCC1 tumor-bearing athymic nude mice by static and dynamic microPET imaging. Ex vivo biodistribution assays were performed to confirm the noninvasive imaging results. RESULTS: The radiolabeling yield for [(18)F]FBEM-cEGF was over 60%, based on starting [(18)F]FBEM. [(18)F]FBEM-cEGF exhibited rapid blood clearance through both hepatobiliary and renal excretion. UM-SCC1 tumors were clearly visualized and showed modest tracer uptake of 2.60 ± 0.59 %ID/g at 30 min after injection. Significantly higher tumor uptake of [(18)F]FBEM-cEGF (5.99 ± 1.61%ID/g at 30 min after injection, p < 0.01) and tumor/nontumor ratio were achieved by coinjection of 50 μg of unlabeled EGF. Decreased liver uptake of [(18)F]FBEM-cEGF was observed when unlabeled EGF was coadministered. CONCLUSION: With optimized liver blocking, [(18)F]FBEM-cEGF has the potential to be used in a noninvasive and quantitative manner for detection of malignant lesions and evaluation of EGFR activity.
PURPOSE: To prepare and evaluate a new radiotracer for molecular imaging of cell surface receptors for epidermal growth factor (EGF). METHODS:Cys-tagged EGF (cEGF) was labeled with (18)F by coupling the free thiol group of the Cys tag with N-[2-(4-[(18)F]fluorobenzamido)ethyl]maleimide ([(18)F]FBEM) to form [(18)F]FBEM-cEGF. Cell uptake, internalization and efflux of [(18)F]FBEM-cEGF were tested in human head and neck squamous carcinomaUM-SCC1 cells. In vivo tumor targeting and pharmacokinetics of the radiotracers were evaluated in UM-SCC1tumor-bearing athymic nude mice by static and dynamic microPET imaging. Ex vivo biodistribution assays were performed to confirm the noninvasive imaging results. RESULTS: The radiolabeling yield for [(18)F]FBEM-cEGF was over 60%, based on starting [(18)F]FBEM. [(18)F]FBEM-cEGF exhibited rapid blood clearance through both hepatobiliary and renal excretion. UM-SCC1tumors were clearly visualized and showed modest tracer uptake of 2.60 ± 0.59 %ID/g at 30 min after injection. Significantly higher tumor uptake of [(18)F]FBEM-cEGF (5.99 ± 1.61%ID/g at 30 min after injection, p < 0.01) and tumor/nontumor ratio were achieved by coinjection of 50 μg of unlabeled EGF. Decreased liver uptake of [(18)F]FBEM-cEGF was observed when unlabeled EGF was coadministered. CONCLUSION: With optimized liver blocking, [(18)F]FBEM-cEGF has the potential to be used in a noninvasive and quantitative manner for detection of malignant lesions and evaluation of EGFR activity.
Authors: F Scopinaro; G De Vincentis; M Banci; O Schillaci; M Di Loreto; R Danieli; M Ierardi; A M De Paola; W Gianni; R Massa Journal: Anticancer Res Date: 1997 May-Jun Impact factor: 2.480
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: C R Divgi; S Welt; M Kris; F X Real; S D Yeh; R Gralla; B Merchant; S Schweighart; M Unger; S M Larson Journal: J Natl Cancer Inst Date: 1991-01-16 Impact factor: 13.506
Authors: Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Richard S Agnes; Ann-Marie Broome; Jing Wang; Anjali Verma; Kari Lavik; James P Basilion Journal: Mol Cancer Ther Date: 2012-07-17 Impact factor: 6.261
Authors: Kirstin A Zettlitz; Richard Tavaré; Wen-Ting K Tsai; Reiko E Yamada; Noel S Ha; Jeffrey Collins; R Michael van Dam; John M Timmerman; Anna M Wu Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-19 Impact factor: 9.236
Authors: Lemonitsa H Mammatas; Henk M W Verheul; N Harry Hendrikse; Maqsood Yaqub; Adriaan A Lammertsma; C Willemien Menke-van der Houven van Oordt Journal: Cell Oncol (Dordr) Date: 2014-09-24 Impact factor: 6.730
Authors: Javad Garousi; Ken G Andersson; Bogdan Mitran; Marie-Louise Pichl; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev Journal: Int J Oncol Date: 2016-02-02 Impact factor: 5.650